Last reviewed · How we verify
Glucagon-like peptide-1 receptor agonist：Semaglutide
Glucagon-like peptide-1 receptor agonist：Semaglutide is a Small molecule drug developed by The First Affiliated Hospital with Nanjing Medical University. It is currently FDA-approved. Also known as: Semaglutide.
At a glance
| Generic name | Glucagon-like peptide-1 receptor agonist：Semaglutide |
|---|---|
| Also known as | Semaglutide |
| Sponsor | The First Affiliated Hospital with Nanjing Medical University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Glucagon-like peptide-1 receptor agonist：Semaglutide CI brief — competitive landscape report
- Glucagon-like peptide-1 receptor agonist：Semaglutide updates RSS · CI watch RSS
- The First Affiliated Hospital with Nanjing Medical University portfolio CI
Frequently asked questions about Glucagon-like peptide-1 receptor agonist：Semaglutide
What is Glucagon-like peptide-1 receptor agonist：Semaglutide?
Glucagon-like peptide-1 receptor agonist：Semaglutide is a Small molecule drug developed by The First Affiliated Hospital with Nanjing Medical University.
Who makes Glucagon-like peptide-1 receptor agonist：Semaglutide?
Glucagon-like peptide-1 receptor agonist：Semaglutide is developed and marketed by The First Affiliated Hospital with Nanjing Medical University (see full The First Affiliated Hospital with Nanjing Medical University pipeline at /company/the-first-affiliated-hospital-with-nanjing-medical-university).
Is Glucagon-like peptide-1 receptor agonist：Semaglutide also known as anything else?
Glucagon-like peptide-1 receptor agonist：Semaglutide is also known as Semaglutide.
What development phase is Glucagon-like peptide-1 receptor agonist：Semaglutide in?
Glucagon-like peptide-1 receptor agonist：Semaglutide is FDA-approved (marketed).
Related
- Manufacturer: The First Affiliated Hospital with Nanjing Medical University — full pipeline
- Also known as: Semaglutide
- Compare: Glucagon-like peptide-1 receptor agonist：Semaglutide vs similar drugs
- Pricing: Glucagon-like peptide-1 receptor agonist：Semaglutide cost, discount & access